Gram-Positive Bacterial Infections is an indication for drug development with over 520 pipeline drugs currently active. According to GlobalData, preregistered drugs for Gram-Positive Bacterial Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Gram-Positive Bacterial Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gram-Positive Bacterial Infections overview

Gram-positive bacterial infections are caused by bacteria that have a thick cell wall and stain blue or purple when exposed to a chemical called Gram stain. Gram-positive bacteria can be classified into cocci (spherical shape) or bacilli (rod shape) based on their morphology. Some examples of Gram-positive cocci are Staphylococcus, Streptococcus, and Enterococcus, which can cause diseases such as pneumonia, skin infections, strep throat, and toxic shock syndrome. Some examples of Gram-positive bacilli are Bacillus, Clostridium, and Listeria, which can cause diseases such as anthrax, botulism, and listeriosis. Gram-positive bacterial infections are treated with antibiotics that target the cell wall or the peptidoglycan layer, such as penicillins, cephalosporins, and vancomycin. However, some Gram-positive bacteria have developed resistance to these antibiotics, making them harder to treat. Therefore, it is important to identify the type and sensitivity of the bacteria before prescribing the appropriate antibiotic.

For a complete picture of PTSR and LoA scores for drugs in Gram-Positive Bacterial Infections, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.